On Monday, Scotiabank maintained its optimistic outlook for Myriad Genetics (NASDAQ:MYGN), a global leader in personalized medicine. The firm reiterated its Sector Outperform rating and a price target of $34.00 for the company's stock. The affirmation followed Myriad Genetics' Investor Day, which was held on Sunday, where the company outlined its strategic objectives and financial targets.
The company's management set forth an ambitious goal to achieve double-digit top-line growth, aiming to surpass $1 billion in revenues by 2026. This growth is expected to be driven by a streamlined product portfolio. Alongside revenue growth, Myriad Genetics is also targeting double-digit EBITDA margins within the same timeframe. The emphasis on operational excellence is seen as a key driver for this financial aspiration.
In addition to financial targets, Myriad Genetics discussed its pipeline development priorities. The focus here is on enhancing the company's competitive position in the market. This includes the development of new products and services that are expected to contribute to the company's growth and market share.
Scotiabank's analyst highlighted these key takeaways from the Investor Day and noted that despite the ambitious plans, the firm's current model and estimates for Myriad Genetics remain unchanged. The reiterated Sector Outperform rating and price target reflect Scotiabank's confidence in Myriad Genetics' strategic direction and potential for growth.
Investors and stakeholders in Myriad Genetics can look forward to the company's progress as it works towards its stated goals, with the potential for significant financial performance enhancements over the next few years.
In other recent news, Myriad Genetics reported third-quarter revenue figures between $210-212 million, surpassing the Street's expectation of $210 million, and reaffirmed its 2024 revenue guidance of $835-845 million. Stephens increased the stock target for Myriad Genetics, reflecting an optimistic growth outlook, particularly in light of the expected surge in global LNG supply.
Leerink Partners also increased their price target for Myriad Genetics to $40, maintaining an Outperform rating on the shares. However, JPMorgan reiterated its Underweight rating on Myriad Genetics, maintaining a $20 price target, while BofA Securities held an Underperform rating for the company. These recent developments highlight the differing views of analysts on the company's future performance.
Myriad Genetics also announced collaborations with The University of Texas MD Anderson Cancer Center and The University of Rochester Medical Center, focusing on breast cancer molecular residual disease testing research. The company's Precise MRD test is anticipated to launch commercially in 2026.
Despite discontinuing part of its GeneSight study, Wells Fargo listed Myriad Genetics among its high-conviction ideas for sustained growth into 2025. The company's strategic initiatives and recent partnerships demonstrate its commitment to growth and innovation in the field of genetic testing.
InvestingPro Insights
Myriad Genetics' ambitious growth plans, as outlined in their Investor Day, are reflected in some of the company's recent financial metrics. According to InvestingPro data, Myriad Genetics has shown strong revenue growth, with a 14.78% increase over the last twelve months as of Q2 2024, and an even more impressive 15.26% quarterly growth in Q2 2024. This aligns well with the company's goal of achieving double-digit top-line growth.
However, it is important to note that the company is currently not profitable, with a negative operating income of $103.3 million over the last twelve months. This underscores the importance of Myriad Genetics' focus on operational excellence to achieve their targeted double-digit EBITDA margins by 2026.
InvestingPro Tips highlight that while the stock has taken a big hit over the last week, it has shown a high return over the last year, with a 65.61% price total return. This volatility could present opportunities for investors as the company works towards its ambitious goals.
For those interested in a deeper analysis, InvestingPro offers 7 additional tips for Myriad Genetics, providing further insights into the company's financial health and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.